SOPHiA GENETICS (NASDAQ:SOPH) CEO Jurgi Camblong Sells 4,399 Shares

Key Points

• CEO Jurgi Camblong sold 4,399 shares on April 13 at an average of $4.76 (about $20,939) under a pre-arranged Rule 10b5-1 plan to cover tax withholding from vested equity, leaving him with 3,707,569 shares (a 0.12% ownership decrease); he sold roughly 30,967 shares across several recent transactions.
• SOPHiA GENETICS shares traded up 2.3% to $4.96, but the company reported a quarterly EPS miss (‑$0.28 vs. ‑$0.20 expected) with negative margins and a forecasted negative full-year EPS, while analysts hold a consensus rating of "Hold" with a $7.00 price target.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) CEO Jurgi Camblong sold 4,399 shares of the stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $4.76, for a total value of $20,939.24. Following the transaction, the chief executive officer directly owned 3,707,569 shares of the company's stock, valued at $17,648,028.44. This trade represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jurgi Camblong also recently made the following trade(s):

• On Friday, April 10th, Jurgi Camblong sold 12,232 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.72, for a total value of $57,735.04.
• On Thursday, April 9th, Jurgi Camblong sold 1,950 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,243.00.
• On Wednesday, April 8th, Jurgi Camblong sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total value of $13,552.00.
• On Tuesday, April 7th, Jurgi Camblong sold 2,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.86, for a total value of $12,150.00.
• On Monday, April 6th, Jurgi Camblong sold 2,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total value of $12,610.00.
• On Thursday, March 19th, Jurgi Camblong sold 4,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.77, for a total value of $21,398.22.

SOPHiA GENETICS Stock Up 2.3%

NASDAQ SOPH traded up $0.11 during trading hours on Tuesday, hitting $4.96. 148,768 shares of the company traded hands, compared to its average volume of 183,135. The business's 50-day moving average is $4.74 and its 200-day moving average is $4.71. SOPHiA GENETICS SA has a twelve month low of $2.58 and a twelve month high of $5.70. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96. The stock has a market capitalization of $339.71 million, a price-to-earnings ratio of -9.73 and a beta of 1.04.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The company had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million. Sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on SOPH. BTIG Research restated a "buy" rating and issued a $7.00 price objective on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Guggenheim upped their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, SOPHiA GENETICS has a consensus rating of "Hold" and a consensus price target of $7.00.

Institutional Trading of SOPHiA GENETICS

Several institutional investors and hedge funds have recently bought and sold shares of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company's stock valued at $25,341,000 after buying an additional 5,432,871 shares during the period. Federated Hermes Inc. raised its stake in SOPHiA GENETICS by 16.4% in the second quarter. Federated Hermes Inc. now owns 220,000 shares of the company's stock valued at $682,000 after buying an additional 31,000 shares during the period. Akre Capital Management LLC raised its stake in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company's stock valued at $11,529,000 after buying an additional 1,481,636 shares during the period. Alta Wealth Advisors LLC bought a new stake in SOPHiA GENETICS in the third quarter valued at approximately $6,708,000. Finally, Savvy Advisors Inc. bought a new stake in SOPHiA GENETICS in the third quarter valued at approximately $48,000. Institutional investors own 31.59% of the company's stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.